Enalees launches Rhéa®, new range of rapid molecular tests intended for ruminants
Launch marks strategic milestone in Enalees' industrial and technological development, with first production plant set to become operational in France in 2026
Enaleesits new range of rapid molecular diagnostic tests for cattle, sheep and goats. This innovation marks a strategic step in terms of R&D development for Enalees, following its international rollout of two ranges of tests – one for horses and the other for cats and dogs.
A reliable and rapid point-of-care diagnostic solution, designed especially for rural veterinarians
The Rhéa® range addresses a growing need in the sector: enabling veterinarians to act quickly and accurately in the field, even in the most remote areas, by diagnosing, then treating, ruminants on site, without the need for a laboratory. The first panel test available, Rhéa® Vector-Borne Diseases, simultaneously detects four major pathogens in under 40 minutes, directly in the field: Theileria spp., Babesia spp., Anaplasma spp. (including A. marginale and A. phagocytophilum), and Borrelia spp. These pathogens can also be detected in a monovalent format.
Together, these four pathogens can seriously affect the health and productivity of animals.
Accessible 24/7 without a cumbersome laboratory infrastructure (unlike traditional PCR tests), Rhéa® guarantees veterinarians:
Complete diagnostic autonomy
Rapid clinical decision-making, for targeted treatment or immediate biosecurity measures
Improved continuity in the agricultural sector’s production and logistics chains
Laurent Thiery, president and co-founder of Enalees:
“Rhéa® is a powerful symbol of our commitment; bringing innovation to field veterinarians using simple, reliable tools tailored to the demands of rural veterinary medicine.”
An innovation-driven approach supported by new financing and R&D efforts
The expansion of Enalees’ rapid test range to include the livestock sector opens up a market three times larger than that of the pet sector, offering targeted solutions for cattle, poultry, pigs, sheep and goats.
This innovation strategy has been made possible by the €15 million fundraising round completed in 2024, as well as support from the public France 2030 initiative– the Première Usine (First Factory) program – through which Enalees received a non-dilutive grant of €2.7 million in 2025 to build its first production plant in France.
The global veterinary diagnostics market is expected to reach $9.5 billion by 2026, exhibiting a CAGR of 10% during the forecast period.
The Rhéa® range of tests will be available from June 2025.
About Enalees
Enalees develops, manufactures and markets rapid isothermal PCR tests that enable veterinarians to diagnose suspected infectious diseases – either in the clinic or directly in the field – without the need to send samples to a specialized laboratory. Its team, mainly made up of doctors, veterinarians and biology engineers and technicians, develops innovative tests for both pets and livestock.
The tests use LAMP technology. This allows the amplification of the DNA sequence and offers four advantages: specificity and a sensitivity equivalent to PCR, while combining rapid results with robustness.
Enalees offers more than 60 tests via three ranges: Epona® (horses), Astéria® (dogs/cats) and Rhéa® (ruminants). These can detect more than 25 infectious diseases, including rhinopneumonitis, flu, borreliosis (the pathogen that causes Lyme disease), even leptospirosis.
The Enalees facilities (R&D and production) have been at the Genopole Biocluster in Essonne, France since 2016. Enalees has a production capacity of one million units per year, serving its own animal health business and its partners, for whom it develops and manufactures custom tests.
Enalees currently has 43 employees globally.
Contact Enalees
Florence Fombertasse
Marketing and communications director
+33 (0)749 329 506